symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
CLVLY,10.0132,0.767379,4392,494755216,0.03,8.76-19.98,0.1132,Clinuvel Pharmaceuticals Limited,USD,0001290877,US1887691038,188769103,Other OTC,PNK,Biotechnology,https://www.clinuvel.com,"Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÃ‰NUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.","Dr. Philippe Jacques Wolgen M.B.A., M.D., MBA",Healthcare,AU,,61 3 9660 4900,535 Bourke Street,Melbourne,VIC,3000,,0,https://financialmodelingprep.com/image-stock/CLVLY.png,2008-01-30,False,False,True,False,False
